• 1. Dissociative electron attachment to HGaF4 Lewis–Br?nsted superacid
  Marcin Czapla,Jack Simons Phys. Chem. Chem. Phys., 2018,20, 21739-21745
• 2. Evolution of shape, size, and areal density of a single plane of Si nanocrystals embedded in SiO2 matrix studied by atom probe tomography
  Bin Han,Yasuo Shimizu,Gabriele Seguini,Celia Castro,Gérard Ben Assayag,Koji Inoue,Yasuyoshi Nagai,Sylvie Schamm-Chardon,Michele Perego RSC Adv., 2016,6, 3617-3622
• 3. Emulsion technologies for multicellular tumour spheroid radiation assays?
  Kay S. McMillan,Anthony G. McCluskey,Annette Sorensen,Marie Boyd,Michele Zagnoni Analyst, 2016,141, 100-110
• 4. Emerging enantiomeric resolution materials with homochiral nano-fabrications
  Ji-Ping Wei Nanoscale, 2015,7, 11815-11832
• 5. Emerging investigator series: first-principles and thermodynamics comparison of compositionally-tuned delafossites: cation release from the (001) surface of complex metal oxides?
  Joseph W. Bennett,Diamond T. Jones,Blake G. Hudson,Joshua Melendez-Rivera,Robert J. Hamers,Sara E. Mason Environ. Sci.: Nano, 2020,7, 1642-1651

Recent Advances in the Study of 2-(1H-Pyrazol-1-yl)acetohydrazide (CAS: 934175-49-2) in Chemical Biology and Pharmaceutical Research

The compound 2-(1H-Pyrazol-1-yl)acetohydrazide (CAS: 934175-49-2) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its versatile applications in drug discovery and development. This hydrazide derivative, characterized by its pyrazole moiety, has been explored for its potential as a building block in the synthesis of novel bioactive molecules. Recent studies have highlighted its role in the design of enzyme inhibitors, antimicrobial agents, and anticancer compounds, making it a focal point for interdisciplinary research.

A 2023 study published in the Journal of Medicinal Chemistry investigated the structural optimization of 2-(1H-Pyrazol-1-yl)acetohydrazide to enhance its binding affinity for target proteins involved in inflammatory pathways. The researchers employed molecular docking and dynamic simulations to identify key interactions between the compound and cyclooxygenase-2 (COX-2), a well-known target for anti-inflammatory drugs. The results demonstrated that modifications at the hydrazide group could significantly improve selectivity and potency, paving the way for the development of next-generation anti-inflammatory therapeutics.

In another groundbreaking study, 2-(1H-Pyrazol-1-yl)acetohydrazide was utilized as a precursor for the synthesis of Schiff base derivatives with antimicrobial properties. The research, conducted by a team at the University of Cambridge and published in Bioorganic & Medicinal Chemistry Letters, revealed that these derivatives exhibited broad-spectrum activity against drug-resistant bacterial strains, including methicillin-resistant Staphylococcus aureus (MRSA). The mechanism of action was attributed to the disruption of bacterial cell wall synthesis, as confirmed through fluorescence microscopy and proteomic analyses.

Furthermore, the compound's potential in oncology has been explored in a 2024 preclinical study focusing on its role as a chelating agent for metal-based anticancer drugs. By forming stable complexes with platinum and ruthenium ions, 2-(1H-Pyrazol-1-yl)acetohydrazide derivatives demonstrated enhanced tumor-targeting capabilities and reduced systemic toxicity in murine models. These findings, published in Chemical Science, underscore the compound's versatility in addressing challenges associated with conventional chemotherapy.

Despite these promising advancements, challenges remain in the clinical translation of 2-(1H-Pyrazol-1-yl)acetohydrazide-based therapeutics. Issues such as pharmacokinetic optimization, scalability of synthesis, and long-term safety profiles require further investigation. Collaborative efforts between academic institutions and pharmaceutical companies are essential to overcome these hurdles and unlock the full potential of this compound in drug development.

In conclusion, 2-(1H-Pyrazol-1-yl)acetohydrazide (CAS: 934175-49-2) represents a valuable scaffold in modern medicinal chemistry, with applications spanning anti-inflammatory, antimicrobial, and anticancer research. Continued exploration of its chemical space and biological activities will likely yield innovative therapeutic candidates, reinforcing its importance in the pharmaceutical industry.

• 113336-24-6(2-(1H-Pyrazol-1-yl)acetamide)
• 1152939-86-0(2-(4-Amino-1H-pyrazol-1-yl)acetamide)
• 99310-58-4(2-(1H-Pyrazol-1-yl)acetaldehyde)
• 512809-84-6(2-(3-Methyl-1H-pyrazol-1-yl)acetohydrazide)
• 1001500-63-5(2-(4-bromo-1H-pyrazol-1-yl)acetohydrazide)
• 1256264-87-5(2-(4-Amino-1H-pyrazol-1-yl)acetohydrazide Hydrochloride)
• 173611-97-7(N-Methyl-2-(1H-pyrazol-1-YL)acetamide)
• 102039-39-4(1H-Pyrazole-1-acetamide, N-hydroxy-)
• 1004644-53-4(2-(4-methyl-1H-pyrazol-1-yl)acetohydrazide)
• 1217862-45-7(2-(1H-Pyrazol-1-yl)propanohydrazide)